Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Unstable angina is a common cardiovascular condition associated with major adverse clinical events. Over the last 15 years, therapeutic advances have dramatically reduced the complication and mortality rates of this serious condition. The standard of therapy in patients with unstable angina now incorporates the combined use of potent antithrombotic (aspirin, clopidogrel, heparin and glycoprotein IIb/IIIa receptor antagonists) and anti-anginal (beta-blockade and intravenous nitrates) regimens complemented by the selective and judicious application of coronary revascularisation strategies. Increasingly, these invasive and non-invasive therapeutic interventions are being guided not only by the clinical risk profile but also by the determination of serum cardiac and inflammatory markers. Moreover, rapid and intensive management of associated risk factors, such as hypercholesterolaemia, would appear to have potentially substantial benefits even within the acute in-hospital phase of unstable angina.

Original publication

DOI

10.1093/bmb/59.1.69

Type

Journal article

Journal

Br med bull

Publication Date

2001

Volume

59

Pages

69 - 87

Keywords

Aged, Angina, Unstable, Angioplasty, Balloon, Coronary, C-Reactive Protein, Coronary Artery Bypass, Coronary Restenosis, Electrocardiography, Emergency Treatment, Hospitalization, Humans, Middle Aged, Myocardial Revascularization, Potassium Channels, Risk Assessment, Time Factors, Troponin